Please login to the form below

Not currently logged in
Email:
Password:

Tobi Podhaler

This page shows the latest Tobi Podhaler news and features for those working in and with pharma, biotech and healthcare.

NICE backs Novartis/ ThromboGenics’ eye drug

NICE backs Novartis/ ThromboGenics’ eye drug

ranibizumab). Novartis has also won the cost-effectiveness watchdog's backing in 2013 for the Tobi Podhaler (tobramycin), a treatment for cystic fibrosis.

Latest news

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...